Open Journal Systems

Cover Image

Vogt-koyanagi-harada disease: A potentially debilitating diagnosis of exclusion

Tungki Pratama Umar, Reynold Siburian


Background: Vogt-Koyanagi-Harada (VKH) disease is a systemic autoimmune granulomatous disease that targets melanocyte-rich tissue with potentially visually-threatening outcome for patients. It is manifested in eyes, inner ears, skin, and hair. Aim: This review aims to give a brief information about VKH disease, especially regarding the diagnosis and treatment. Conclusion: VKH disease is a diagnosis of exclusion, a comprehensive history taking and physical examinations are required for prompt treatment using immunosuppressive agent to improve patient outcomes. Clinical Significance: It is possible to treat this condition by applying diagnostic criteria. This requires a very thorough review of possible differential diagnosis and should then be treated with high corticosteroid immunosuppressive drugs. This is solely responsible for stopping the visual impairment and recurrence of the disease.


Corticosteroids; Human leukocyte antigen; Immunomodulator; Immunosuppressive agent; Vogt-Koyanagi-Harada disease

Full Text:

Abstract PDF


Lavezzo MM, Sakata VM, Morita C, Rodriguez EE, Abdallah SF, da Silva FT, et al. Vogt-Koyanagi-Harada disease: Review of a rare autoimmune disease targeting antigens of melanocytes. Orphanet J Rare Dis 2016;11:29.

Baltmr A, Lightman S, Tomkins-Netzer O. Vogt-Koyanagi- Harada syndrome - current perspectives. Clin Ophthalmol 2016;10:2345-61.

Patil YB, Garg R, Rajguru JP, Sirsalmath M, Bevinakatti VA, Kumar M, et al. Vogt-Koyanagi-Harada (VKH) syndrome: A new perspective for healthcare professionals. J Fam Med Prim Care 2020;9:31-5.

Hernandez-Camarena J, Gonzalez-Gonzalez LA, Shaikh M, Rodríguez-García A, Foster CS. Vogt-Koyanagi-Harada syndrome. Contemp Ophthalmol 2010;9:1-7.

Herbort CP, Mochizuki M. Vogt-Koyanagi-Harada disease: Inquiry into the genesis of a disease name in the historical context of Switzerland and Japan. Int Ophthalmol 2007;27:67-79.

Silpa-Archa S, Noonpradej S, Amphornphruet A. Pattern of uveitis in a referral ophthalmology center in the central district of Thailand. Ocul Immunol Inflamm 2015;23:320-8.

Al Dhahri H, Al Rubaie K, Hemachandran S, Mousa A, Gikandi P, Al-Mezaine H, et al. Patterns of uveitis in a university-based tertiary referral center in Riyadh, Saudi Arabia. Ocul Immunol Inflamm 2015;23:311-9.

Wang Y, Chan C. Gender differences in Vogt-Koyanagi- Harada disease and sympathetic ophthalmia. J Ophtalmol 2014;2014:157803.

O’Keefe GA, Rao NA. Vogt-Koyanagi-Harada disease. Surv Ophthalmol 2017;62:1-25.

Elahi S, Herbort CP Jr. Vogt-Koyanagi-Harada disease and birdshot retinochoroidopathy, similarities and differences: A glimpse into the clinicopathology of stromal choroiditis, a perspective and a review. Klin Monatsbl Augenheilkd 2019;236:492-510.

Marcelo TT, Iguban EB. A case report on Vogt-Koyanagi- Harada disease seen at a tertiary hospital in the Philippines. Ophthalmol Open J 2018;3:1-4.

Johal B, Johal H, Lukaris A. The clinical presentation and diagnosis of Vogt-Koyanagi-Harada syndrome. Univ Br Columbia Med J 2015;6:20-2.

Yang P, Zhong Y, Du L, Chi W, Chen L, Zhang R, et al. Development and evaluation of diagnostic criteria for Vogt- Koyanagi-Harada disease. JAMA Ophthalmol 2018;136:1025-31.

Crosson JN, Laird PW, Debiec M, Bergstrom CS, Lawson DH, Yeh S. Vogt-Koyanagi-Harada-like syndrome after CTLA- 4 inhibition with ipilimumab for metastatic melanoma. J Immunother 2015;38:80-4.

Lodhi S, Reddy J, Peram V. Clinical spectrum and management options in Vogt-Koyanagi-Harada disease. Clin Ophthalmol 2017;11:1399-406.

Urzua CA. Vogt-Koyanagi-Harada disease. In: Rodriguez-Garcia A, Foster CS, editors. Advances in the Diagnosis and Management of Uveitis. 1st ed. London: Intech Open; 2019. p. 9-18.

Bassili S, Peyman G, Gebhardt B, Daun M, Ganiban G, Rifai A. Detection of Epstein-Barr virus DNA by polymerase chain reaction in the vitreous from a patient with Vogt-Koyanagi- Harada syndrome. Retina 1996;16:160-1.

Sugita S, Takase H, Kawaguchi T, Taguchi C, Mochizuki M. Cross-reaction between tyrosinase peptides and cytomegalovirus antigen by T cells from patients with Vogt-Koyanagi-Harada disease. Int Ophthalmol 2007;27:87-95.

Damico FM, Bezerra FT, da Silva GC, Gasparin F, Yamamoto JH. New insights into Vogt-Koyanagi-Harada disease. Arq Bras Oftalmol 2009;72(3):413-20.

Adam M, Rahimy E, Dunn J. Tattoo-associated uveitis. JAMA Ophthalmol 2015;133:e144543.

Concha del Río L, Arellanes-García L. Vogt-Koyanagi- Harada disease in the developing world. Int Ophthalmol Clin 2010;50:189-99.

Rao PK, Rao NA. Vogt-Koyanagi-Harada disease and sympathetic ophthalmia. In: Pleyer U, Foster CS, editors. Uveitis and Immunological Disorders. 1st ed. Berlin: Springer; 2007. p. 145-55.

Salcedo HR, Palestine A, Feldman BH, Fingerhut D, O’Keefe GD, Salcedo HR, et al. Vogt-Koyanagi-Harada Disease. EyeWiki; 2019 Available from: Harada_disease. [Last accessed on 2020 Apr 18].

Mota LA, dos Santos AB. Vogt-Koyanagi-Harada syndrome and its multisystem involvement. Rev Assoc Med Bras (1992) 2010;56:590-5.

Salmon JF. Kanski’s Clinical Ophthalmology. 9th ed. New York: Elsevier; 2019. p. 445-7.

Knecht P, Mantovani A, Herbort C. Indocyanine green angiography-guided management of Vogt-Koyanagi-Harada disease: Differentiation between choroidal scars and active lesions. Int Ophthalmol 2013;33:571-7.

Mai AP, Tran C, Wilson CW, Fox AR, Boldt HC. Vogt-Koyanagi- Harada (VKH) Disease. EyeRounds; 2019. Available from: htm. [Last accessed on 2020 Apr 18].

Herbort CP, Abu El Asrar AM, Yamamoto JH, Pavésio CE, Gupta V, Khairallah M, et al. Reappraisal of the management of Vogt-Koyanagi-Harada disease: Sunset glow fundus is no more a fatality. Int Ophthalmol 2017;37:1383-95.

Urzua C, Velasquez V, Sabat P, Berger O, Ramirez S, Goecke A, et al. Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt- Koyanagi-Harada disease. Acta Ophthalmol 2015;93:475-80.

Bouchenaki N, Morisod L, Herbort CP. Vogt-Koyanagi-Harada syndrome: Importance of rapid diagnosis and therapeutic intervention. Klin Monbl Augenheilkd 2000;216:290-4.

Read RW, Yu F, Accorinti M, Bodaghi B, Chee SP, Fardeau C, et al. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi- Harada disease. Am J Ophthalmol 2006;142:119-24.

Bouchenaki N, Herbort CP. Indocyanine green angiography guided management of vogt-koyanagi-harada disease. J Ophthalmic Vis Res 2011;6:241-8.

Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS, Kangave D, Al-Muammar AM. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol 2012;90:e603-8.

El-Asrar AMA, Dosari M, Hemachandran S, Gikandi PW, Al- Muammar A. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘sunset glow fundus’ in initial-onset acute uveitis associated with Vogt-Koyanagi- Harada disease. Acta Ophthalmol 2017;95:85-90.

Manethova K, Ernest J, Hrevus M. Vogt-Koyanagi-Harada syndrome (uveomeningoencephalitic syndrome). Eur J Ophthalmol 2017;27:e5-8.

Akram S, Ahmad K. Vogt-Koyanagi-Harada syndrome. J Coll Physicians Surg Pak 2014;24(9):692-4.

Hosseini SM, Dourandish M, Mazouchi M. Unilateral presentation of Vogt-Koyanagi-Harada syndrome. J Ophthalmic Vis Res 2020;15:99-103.

Yuan F, Zhang Y, Yan X. Bilateral acute angle closure glaucoma as an initial presentation of Vogt-Koyanagi-Harada syndrome: A clinical case report. Eur J Ophthalmol 2020:1120672120951442. Doi: 10.1177/1120672120951442.

Ali S, Oo HH, Agarwal R, Khee PK. Concurrent presence of retinal hemorrhages in the setting of acute Vogt-Koyanagi- Harada syndrome - an unusual presentation. J Ophthalmic Inflamm Infect 2020;10:1-4.

Nichani P, Christakis PG, Micieli J. Headache and bilateral optic disc edema as the initial manifestation of Vogt-Koyanagi- Harada disease. J Neuroophthalmol 2020;41:e128-30.

Kurono Y, Takeda T, Kunimatsu Y, Tani N, Hashimoto I, Hirose K. Vogt-Koyanagi-Harada disease during chemoimmunotherapy for non‐small cell lung cancer. Respirol Case Rep 2020;8:e00545.

Kikuchi R, Kawagoe T, Hotta K. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: A case report. BMC Ophthalmol 2020;20:1-6.


  • There are currently no refbacks.